https://neurimmune.com/science 2026-01-28T15:10:13+00:00 https://neurimmune.com/company 2026-02-05T12:54:17+00:00 https://neurimmune.com/pipeline 2026-03-12T20:40:48+00:00 https://neurimmune.com/contact 2026-03-13T07:21:40+00:00 https://neurimmune.com/legal-notice 2026-03-15T17:48:37+00:00 https://neurimmune.com/privacy-policy 2026-03-15T18:02:13+00:00 https://neurimmune.com/pipeline/ni101b3 2026-03-16T09:48:30+00:00 https://neurimmune.com/science/rtm-technology 2026-03-16T12:32:01+00:00 https://neurimmune.com/science/publications 2026-03-16T12:32:52+00:00 https://neurimmune.com/pipeline/pipeline-overview 2026-03-16T12:37:08+00:00 https://neurimmune.com/pipeline/ap-101 2026-03-16T12:37:43+00:00 https://neurimmune.com/company/news 2026-03-16T12:40:06+00:00 https://neurimmune.com/company/pioneers-of-vitality 2026-03-16T12:42:05+00:00 https://neurimmune.com/company/careers 2026-03-16T12:42:38+00:00 https://neurimmune.com/pipeline/ng004 2026-03-16T12:44:34+00:00 https://neurimmune.com/pipeline/ni009 2026-03-16T12:45:25+00:00 https://neurimmune.com/science/amyloid-depletion 2026-03-16T12:47:26+00:00 https://neurimmune.com/pipeline/cliramitug 2026-03-16T13:10:57+00:00 https://neurimmune.com/company/corporate-engagement 2026-03-19T10:48:56+00:00 https://neurimmune.com/company/about-us 2026-03-20T09:09:40+00:00 https://neurimmune.com/company/mission 2026-03-20T09:10:55+00:00 https://neurimmune.com 2026-03-25T07:55:02+00:00 https://neurimmune.com/team/martin-meier-pfister 2026-01-19T10:24:02+00:00 https://neurimmune.com/team/christine-frei 2026-02-17T08:08:08+00:00 https://neurimmune.com/team/alex-wyden 2026-02-17T08:09:27+00:00 https://neurimmune.com/team/christoph-hock-md 2026-03-13T19:54:38+00:00 https://neurimmune.com/team/jan-grimm-phd 2026-03-13T19:55:12+00:00 https://neurimmune.com/team/fabian-buller-phd 2026-03-14T10:29:51+00:00 https://neurimmune.com/team/roger-m-nitsch-md 2026-03-16T09:22:42+00:00 https://neurimmune.com/team/alfred-w-sandrock-md-phd 2026-03-16T09:28:42+00:00 https://neurimmune.com/team/dirk-schimkat-licrerpol 2026-03-16T09:29:09+00:00 https://neurimmune.com/team/john-dellapa-djur 2026-03-16T12:24:01+00:00 https://neurimmune.com/team/michael-salzmann-phd 2026-03-19T10:48:13+00:00 https://neurimmune.com/publications/release-of-alzheimer-amyloid-precursor-derivatives-stimulated-by-activation-of-muscarinic-acetylcholine-receptors 2026-02-20T12:22:48+00:00 https://neurimmune.com/publications/increased-levels-of-tau-protein-in-cerebrospinal-fluid-of-patients-with-alzheimers-disease-correlation-with-degree-of-cognitive-impairment 2026-02-20T12:24:35+00:00 https://neurimmune.com/publications/formation-of-neurofibrillary-tangles-in-p301l-tau-transgenic-mice-induced-by-abeta-42-fibrils 2026-02-20T12:25:33+00:00 https://neurimmune.com/publications/generation-of-antibodies-specific-for-beta-amyloid-by-vaccination-of-patients-with-alzheimer-disease 2026-02-20T12:26:13+00:00 https://neurimmune.com/publications/antibodies-against-beta-amyloid-slow-cognitive-decline-in-alzheimers-disease 2026-02-20T12:27:30+00:00 https://neurimmune.com/publications/m1-receptors-play-a-central-role-in-modulating-ad-like-pathology-in-transgenic-mice 2026-02-20T12:28:01+00:00 https://neurimmune.com/publications/changes-in-readthrough-acetylcholinesterase-expression-modulate-amyloid-beta-pathology 2026-02-20T12:28:25+00:00 https://neurimmune.com/publications/abeta-immunotherapy-protects-morphology-and-survival-of-adult-born-neurons-in-doubly-transgenic-appps1-mice 2026-02-20T12:28:46+00:00 https://neurimmune.com/publications/beneficial-effect-of-human-anti-amyloid-beta-active-immunization-on-neurite-morphology-and-tau-pathology 2026-02-20T12:29:09+00:00 https://neurimmune.com/publications/broadly-neutralizing-human-monoclonal-jc-polyomavirus-vp1-specific-antibodies-as-candidate-therapeutics-for-progressive-multifocal-leukoencephalopathy 2026-02-20T12:29:33+00:00 https://neurimmune.com/publications/acute-effects-of-muscarinic-m1-receptor-modulation-on-avpp-metabolism-and-amyloid-v-levels-in-vivo-a-microdialysis-study 2026-02-20T12:29:58+00:00 https://neurimmune.com/publications/tau-pathology-dependent-remodelling-of-cerebral-arteries-precedes-alzheimers-disease-related-microvascular-cerebral-amyloid-angiopathy 2026-02-20T12:31:31+00:00 https://neurimmune.com/publications/immunotherapy-with-aducanumab-restores-calcium-homeostasis-in-tg2576-mice 2026-02-20T12:31:56+00:00 https://neurimmune.com/publications/tau-antibody-targeting-pathological-species-blocks-neuronal-uptake-and-interneuron-propagation-of-tau-in-vitro 2026-02-20T12:33:37+00:00 https://neurimmune.com/publications/structural-and-kinetic-basis-for-the-selectivity-of-aducanumab-for-aggregated-forms-of-amyloid-v 2026-02-20T12:34:56+00:00 https://neurimmune.com/publications/development-of-an-aggregate-selective-human-derived-a-synuclein-antibody-biib054-that-ameliorates-disease-phenotypes-in-parkinsons-disease-models 2026-02-20T12:37:07+00:00 https://neurimmune.com/publications/a-human-antibody-selective-for-transthyretin-amyloid-removes-cardiac-amyloid-through-phagocytic-immune-cells 2026-02-20T12:37:31+00:00 https://neurimmune.com/publications/two-randomized-phase-3-studies-of-aducanumab-in-early-alzheimers-disease 2026-02-20T12:37:58+00:00 https://neurimmune.com/publications/prediction-of-cardiac-attr-depletion-by-ni006-alxn2220-using-mechanistic-pkpd-modeling 2026-02-20T12:39:56+00:00 https://neurimmune.com/publications/a-human-derived-antibody-targets-misfolded-sod1-and-ameliorates-motor-symptoms-in-mouse-models-of-amyotrophic-lateral-sclerosis 2026-03-03T15:48:00+00:00 https://neurimmune.com/publications/the-antibody-aducanumab-reduces-av-plaques-in-alzheimers-disease 2026-03-03T15:48:49+00:00 https://neurimmune.com/publications/phase-1-trial-of-antibody-ni006-for-depletion-of-cardiac-transthyretin-amyloid 2026-03-15T17:13:14+00:00 https://neurimmune.com/publications/the-selective-muscarinic-m1-agonist-af102b-decreases-levels-of-total-abeta-in-cerebrospinal-fluid-of-patients-with-alzheimers-disease 2026-03-15T17:14:54+00:00 https://neurimmune.com/publications/release-of-amyloid-beta-protein-precursor-derivatives-by-electrical-depolarization-of-rat-hippocampal-slices 2026-03-15T17:15:13+00:00 https://neurimmune.com/publications/cerebrospinal-fluid-levels-of-amyloid-beta-protein-in-alzheimers-disease-inverse-correlation-with-severity-of-dementia-and-effect-of-apolipoprotein-e-genotype 2026-03-16T07:46:38+00:00 https://neurimmune.com/pipeline/ng004 2026-02-10T13:21:18+00:00 https://neurimmune.com/pipeline/ni504 2026-03-02T10:48:23+00:00 https://neurimmune.com/pipeline/ni101b3p 2026-03-13T13:49:29+00:00 https://neurimmune.com/pipeline/ni009_pipline 2026-03-13T20:08:56+00:00 https://neurimmune.com/pipeline/undisclosed 2026-03-16T12:29:53+00:00 https://neurimmune.com/pipeline/ap-101_p 2026-03-25T11:05:10+00:00 https://neurimmune.com/pipeline/cliramitug-p 2026-03-25T11:05:22+00:00 https://neurimmune.com/news/neurimmune-to-regain-global-rights-to-brain-amyloid-depleter-for-the-treatment-of-alzheimers-disease 2026-03-02T13:36:11+00:00 https://neurimmune.com/news/donald-l-price-memorial-lecture-on-cryo-em-structures-of-disease-filaments-from-human-brains-to-be-presented-at-adpd-2024 2026-03-02T13:36:25+00:00 https://neurimmune.com/news/initiation-of-a-phase-3-study-of-alxn2220-for-the-treatment-of-transthyretin-mediated-amyloid-cardiomyopathy 2026-03-02T13:37:15+00:00 https://neurimmune.com/news/long-term-safety-and-efficacy-of-antibody-alxn2220-for-depletion-of-cardiac-attr-to-be-presented-at-esc-congress-2024 2026-03-02T13:37:26+00:00 https://neurimmune.com/news/fda-fast-track-designation-for-alxn2220-for-depletion-of-cardiac-attr 2026-03-02T13:37:34+00:00 https://neurimmune.com/news/neurimmune-announces-publication-in-clinical-pharmacology-therapeutics-of-the-prediction-of-cardiac-attr-depletion-by-alxn2220 2026-03-02T13:37:46+00:00 https://neurimmune.com/news/echocardiographic-treatment-response-and-long-term-tolerability-of-cardiac-attr-depleter-cliramitug-to-be-presented-at-esc-congress-2025 2026-03-02T13:37:54+00:00 https://neurimmune.com/news/neurimmune-and-aicura-announce-strategic-collaboration-to-leverage-ai-for-the-development-of-alzheimers-disease-therapeutics 2026-03-02T13:38:02+00:00 https://neurimmune.com/news/first-patient-dosed-in-a-follow-on-phase-2-study-evaluating-pharmacodynamics-of-treatment-with-cliramitug-in-patients-with-attr-cardiomyopathy 2026-03-02T13:38:18+00:00 https://neurimmune.com/news/neurimmune-expands-collaboration-with-astrazeneca-to-develop-and-commercialize-fibril-depleter-ni009-for-al-amyloidosis 2026-03-02T13:38:29+00:00 https://neurimmune.com/news/al-s-pharma-reports-positive-results-from-phase-2-study-of-ap-101-for-the-treatment-of-als-supporting-plans-for-a-confirmatory-phase-3-study-1 2026-03-02T13:38:39+00:00 https://neurimmune.com/news/al-s-pharma-announces-positive-topline-results-from-phase-2-study-of-ap-101-for-the-treatment-of-amyotrophic-lateral-sclerosis-als 2026-03-02T13:39:39+00:00 https://neurimmune.com/news/al-s-pharma-appoints-internationally-recognized-neurologist-and-clinical-trial-expert-prof-dr-angela-genge-as-chief-medical-officer 2026-03-02T13:39:47+00:00 https://neurimmune.com/news/al-s-pharma-reports-positive-results-from-phase-2-study-of-ap-101-for-the-treatment-of-als-supporting-plans-for-a-confirmatory-phase-3-study 2026-03-02T13:39:56+00:00 https://neurimmune.com/news/al-s-pharma-to-present-at-the-upcoming-j-p-morgan-2026-annual-healthcare-conference-on-thursday-january-15 2026-03-02T13:40:05+00:00 https://neurimmune.com/news/neurimmune-announces-publication-in-nature-communications-of-its-experimental-therapy-depleting-pathologic-iapp-aggregates-to-protect-beta-cell-health 2026-03-02T14:45:25+00:00 https://neurimmune.com/news/neurimmune-and-astrazeneca-close-exclusive-global-collaboration-and-license-agreement-to-develop-and-commercialize-ni006 2026-03-02T14:51:54+00:00 https://neurimmune.com/news/alfred-w-sandrock-jr-appointed-to-neurimmunes-board-of-directors 2026-03-02T14:53:16+00:00 https://neurimmune.com/news/neurimmune-expands-drug-discovery-collaboration-with-ono-pharmaceutical-in-the-field-of-neurodegenerative-diseases 2026-03-02T14:55:49+00:00 https://neurimmune.com/news/neurimmune-enters-into-a-collaboration-and-license-agreement-with-astrazeneca-to-develop-and-commercialize-ni006 2026-03-12T21:59:49+00:00 https://neurimmune.com/news/keynote-on-the-therapeutic-reversal-of-amyloid-and-tau-pathology-in-alzheimers-disease-to-be-presented-at-the-15th-clinical-trials-on-alzheimers-disease-ctad-conference 2026-03-12T22:00:54+00:00 https://neurimmune.com/news/primary-results-of-the-phase-1b-proof-of-concept-study-of-ni006-to-be-presented-at-the-esc-heart-failure-congress-2023 2026-03-12T22:01:05+00:00 https://neurimmune.com/news/promising-phase-1-results-for-antibody-ni006-in-attr-cardiomyopathy-published-in-the-new-england-journal-of-medicine 2026-03-12T22:01:14+00:00 https://neurimmune.com/news/analysis-of-initial-safety-of-targeted-immune-activation-and-predictive-pkpd-modeling-for-alxn2220-to-be-presented-at-the-heart-failure-2024-congress 2026-03-12T22:01:35+00:00 https://neurimmune.com/news/multiple-poster-presentations-on-alxn2220-for-cardiac-attr-amyloid-depletion-to-be-presented-at-the-xix-international-symposium-on-amyloidosis 2026-03-12T22:01:47+00:00 https://neurimmune.com/news/neurimmune-to-present-key-advances-in-treating-protein-aggregation-diseases-at-adpd-2026 2026-03-18T16:09:03+00:00